ELGX Endologix Inc

Endologix, Inc. (Nasdaq:ELGX) today announced that favorable five-year follow-up data on the Company�s Powerlink� System pivotal clinical trial for the treatment of abdominal aortic aneurysm (AAA) will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2006 conference held in Washington, D.C., on Thursday, October 26. Rodney A. White, M.D., Professor of Surgery at UCLA School of Medicine and Chief of Vascular Surgery at Harbor-UCLA Medical Center, will discuss the data in his presentation �Sac Remodeling After Endoluminal Grafting: Implications for Follow-up Surveillance and Treatment.� Highlights from the Powerlink System five-year follow-up trial data will include: 97.9% of patients were free from AAA mortality There were no aneurysm ruptures There were no stent or graft material failures 86.6% of patients were free from device-related secondary procedures �The clinical data for the Powerlink System is compelling. Endologix has set the bar as it pertains to the durability of the pivotal trial data set, with a 95% compliance of eligible patient follow up at five years as well as core lab 3-D modeling,� said Rodney A. White, M.D. �The fact that we are able to account for nearly all patients, even at extended periods, coupled with strong clinical data, we believe will reassure clinicians on the longer-term reliability of the Powerlink System,� said Paul McCormick, president and chief executive officer of Endologix. �We will continue to update, present and publish long-term clinical data, and we believe this speaks to a key strength of Endologix and the Powerlink System.� About Endologix Endologix, Inc. develops and manufactures minimally invasive treatments for vascular diseases. Endologix's Powerlink System is an endoluminal stent graft (ELG) for treating abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it the thirteenth leading cause of death in the U.S. Additional information can be found on Endologix�s Web site at www.endologix.com. This press release contains forward-looking statements with respect to the acceptance of the Powerlink System by clinicians, the accuracy of which are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix, all as more fully described in the risk factors and other matters set forth in Endologix Annual Report on Form 10-K for the year ended December 31, 2005, and Endologix other filings with the Securities and Exchange Commission. Endologix undertakes no obligation to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Endologix, Inc. (Nasdaq:ELGX) today announced that favorable five-year follow-up data on the Company's Powerlink(R) System pivotal clinical trial for the treatment of abdominal aortic aneurysm (AAA) will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2006 conference held in Washington, D.C., on Thursday, October 26. Rodney A. White, M.D., Professor of Surgery at UCLA School of Medicine and Chief of Vascular Surgery at Harbor-UCLA Medical Center, will discuss the data in his presentation "Sac Remodeling After Endoluminal Grafting: Implications for Follow-up Surveillance and Treatment." Highlights from the Powerlink System five-year follow-up trial data will include: -- 97.9% of patients were free from AAA mortality -- There were no aneurysm ruptures -- There were no stent or graft material failures -- 86.6% of patients were free from device-related secondary procedures "The clinical data for the Powerlink System is compelling. Endologix has set the bar as it pertains to the durability of the pivotal trial data set, with a 95% compliance of eligible patient follow up at five years as well as core lab 3-D modeling," said Rodney A. White, M.D. "The fact that we are able to account for nearly all patients, even at extended periods, coupled with strong clinical data, we believe will reassure clinicians on the longer-term reliability of the Powerlink System," said Paul McCormick, president and chief executive officer of Endologix. "We will continue to update, present and publish long-term clinical data, and we believe this speaks to a key strength of Endologix and the Powerlink System." About Endologix Endologix, Inc. develops and manufactures minimally invasive treatments for vascular diseases. Endologix's Powerlink System is an endoluminal stent graft (ELG) for treating abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it the thirteenth leading cause of death in the U.S. Additional information can be found on Endologix's Web site at www.endologix.com. This press release contains forward-looking statements with respect to the acceptance of the Powerlink System by clinicians, the accuracy of which are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix, all as more fully described in the risk factors and other matters set forth in Endologix Annual Report on Form 10-K for the year ended December 31, 2005, and Endologix other filings with the Securities and Exchange Commission. Endologix undertakes no obligation to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.